Evaluation of microbiological purity of nasal ointment "Mnemastym"
Keywords:nasal ointment “Mnemastym”, arginine-vasopressin, microbiological purity
The aim of this work was the determination of microbiological purity of nasal ointment “Mnemastym” with arginine-vasopressin (AVP).
Materials and methods. For the microbial contamination control the inoculations were made on the nutrient medium set: for colibacillus – Endo agar, for staphylococcus – vitelline-saline agar and for fungi – Sabouraud's glucose agar. Petri dishes with inoculations were incubated during 48 hours at the tempereture 37 °C. Next identification was carried out by the traditional method.
Results. It was determined that amount of microorganisms (bacteria and fungi) in 1 g of composition isn’t more than allowable standard by State Pharmacopoea of Ukraine for this class of dosage forms, but lies near critical value. It is sufficient for extemporaneous compounding of nasal ointment “Mnemastym” but at the same time development of further manufacturing of drug with the adding of antiseptic excipients is necessary. On the base of complex pharmaco-technological, biopharmaceutical, physical-chemical, rheological and biological investigations the optimal composition and technology for compounding of nasal ointment “Mnemastym” for the therapy of cognitive consequences of cerebrovascular pathology were developed.
Conclusions. It was determined that manufacturing of nasal dosage form “Mnemastym” needs an adding of excipients with antimicrobial activity for stabilization of microbial contamination process. It was revealed that for the minimization of this standardization value for the ointment on lipophilic base in pharmacopoeia limit using of polyhexamethylenguanidin phosphate of triclozane or mixture of nipagin: nipazole 8:2 in 0.15 % concentration is the most rationale. Adding of preservatives in nasal ointment with vasopressin on lipophilic base for extemporaneous compounding isn’t need.
Shishkina, A. V., & Bagirova, V. L. (2013) Analiz otechestvennogo farmatsevticheskogo rynka myagkikh lekarstvennykh form [Analysis of the russian plarmaceutical market of soft dosage forms]. Pharmaciya, 1, 28–30. [in Russian].
Obaidi, M., Offman, E., Messina, J., Carothers, J., Djupesland, P. G., & Mahmoud, R. A. (2013) Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder. Headache, 53(8), 1323–1333. doi: 10.1111/head.12167.
Gladyshev, V. V., Almokhamad Zhumaa Abdullakh, Lisyanskaya, A. P., Kechin, I. L., & Biryk, I. A. (2013) Izucheniye vliyaniya osnov-nositeley na intensivnost' vysvobozhdeniya kaptoprila iz nazal'nykh myagkikh lekarstvennykh form [Study of ointment base influence over intensity of captopril release from nasal semisolid dosage forms]. Kubanskij nauchnyj madicinskij vestnik, 5, 69–73. [in Russian].
Al Nukari Abdulkarim, Svirhun, I. S., Lisianska, A. P., Rudko, A. M., & Melkonian, S. A. (2015) Patent Ukrainy na korysnu model vid 10.12.2015 r. №103417 Nazalna maz nootropnoi dii «Mnemastim» [Patent of Ukraine to the utility model dated December 10, 2015 №103417.Nasal ointment of nootprop action]. Bulleten, №23 [in Ukrainian].
Drozdov, O. L., Nahornyi, V. V., & Al Nukari Abdulkarim. (2016) Vyhotovlennia mazi nazalnoi z diiuchoiu rechovynoiu vazopresyn v umovakh apteky [Making of nasal ointment with an operating substance Vasopressinum in the conditions of pharmacy]. Informatsiinyi lyst MOZ Ukrainy z problemy «Farmatsiia», 3(54). [in Ukrainian].
Chebotkevich, V. N., Kaitandghan, E. I., Burylev, V. V., & Shchetinkina, E. E. (2013) Sovremennyye metody laboratornoj diagnostiki sepsisa [Modern Methods for Laboratory Diagnosis of Sepsis]. Laboratornaya diagnostika, 15(4), 295–300. [in Russian].
Almokhamad Zhumaa Abdullakh, Kolycheva, N. L., & Gladysheva, S. A. (2013) Izucheniye mikrobiologicheskoj chistoty nazal'nogo gelya s kaptoprilom [Study of microbiological cleanness of nasal gel with captopril]. Current issues in pharmacy and medicine: science and practice. Abstracts of Papers of the 73rd All-Ukrainian Scientific and Practical Conference of Young Scientists and Students with International Participation, 12, 192. [in Russian].
Draelos, Z. D. (2012) Cosmetics, categories, and the future. Dermatologic Therapy, 25(3), 223–228. doi: 10.1111/j.1529-8019.2012.01498.x.
Kurickaya, T. O., Naumov, N. M., Zheleznyakova, A. A., Volodin, A. D., & Naumov, M. M. (2017) Ispol'zovanie preparatov poligeksametilenguanidin gidrohlorida (PGMG GKH) v lechenii ran [The use of preparations of polyhexamethyleneguanidine hydrochloride (PHMG HCH) is in treatment of wounds]. Regional'nyj vestnik, 1(6), 2–9. [in Russian].
Fox, M. (2016) Animicrobical activity triclozan. NBC News, 2(sep.), 44–51.
Błędzka, D., Gromadzińska, J., & Wąsowicz, W. (2014) From environmental studies to human health. Environment International, 67, 27–42. doi: 10.1016/j.envint.2014.02.007.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)